

You are cordially invited to attend an *ALK+* mNSCLC educational program featuring

Beth Sandy, MSN, CRNP

Nurse Practitioner
University of Pennsylvania
Philadelphia, PA

ALUNBRIG® (brigatinib) Product Overview - 1L PI Based

INDICATION

ALUNBRIG® (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Friday, November 6, 2020 at 12:30 PM PST

<https://cmetracker.net/SCRIPPS/Login?formname=RegLoginLive&eventID=145028>

Please note: This symposium is strictly promotional in nature and not endorsed or accredited by Scripps Health.

Attendance is limited to US Healthcare Professionals.

Takeda acts in accordance with the PhRMA Code on Interactions with Healthcare Professionals. The PhRMA Code states that inclusion of a Healthcare Professional's spouse or guest at an education program is not appropriate. Your support of these ethical guidelines will help to ensure a high quality learning environment for all participating Healthcare Professionals.

SELECTED IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening respiratory symptoms, particularly during the first week of treatment. Withhold ALUNBRIG for new or worsening respiratory symptoms and promptly evaluate for ILD/pneumonitis. Upon recovery, either dose reduce or permanently discontinue ALUNBRIG.

Hypertension: Monitor blood pressure after 2 weeks and then at least monthly during treatment. For severe hypertension, withhold ALUNBRIG, then dose reduce or permanently discontinue.

Please see additional Selected Important Safety Information on the following page and accompanying full Prescribing Information.

SELECTED IMPORTANT SAFETY INFORMATION (CONT'D)

Bradycardia: Monitor heart rate and blood pressure regularly during treatment. If symptomatic, withhold ALUNBRIG® (brigatinib), then dose reduce or permanently discontinue.

Visual Disturbance: Advise patients to report visual symptoms. Withhold ALUNBRIG and obtain ophthalmologic evaluation, then dose reduce or permanently discontinue ALUNBRIG.

Creatine Phosphokinase (CPK) Elevation: Monitor CPK levels regularly during treatment. Based on the severity and with muscle pain or weakness, withhold ALUNBRIG, then resume or reduce dose.

Pancreatic Enzyme Elevation: Monitor lipase and amylase levels regularly during treatment. Based on the severity, withhold ALUNBRIG, then resume or reduce dose.

Hyperglycemia: Assess fasting serum glucose prior to starting ALUNBRIG and regularly during treatment. If not adequately controlled with optimal medical management, withhold ALUNBRIG, then consider dose reduction or permanently discontinue, based on severity.

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use a non-hormonal method of effective contraception.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 25\%$) with ALUNBRIG were diarrhea (49%), fatigue (39%), nausea (39%), rash (38%), cough (37%), myalgia (34%), headache (31%), hypertension (31%), vomiting (27%), and dyspnea (26%).

DRUG INTERACTIONS

CYP3A Inhibitors: Avoid coadministration of ALUNBRIG with strong or moderate CYP3A inhibitors. If coadministration of a strong or moderate CYP3A inhibitor is unavoidable, reduce the dose of ALUNBRIG.

CYP3A Inducers: Avoid coadministration of ALUNBRIG with strong or moderate CYP3A inducers. If coadministration of a moderate CYP3A inducer is unavoidable, increase the dose of ALUNBRIG.

USE IN SPECIFIC POPULATIONS

Hepatic Impairment: Reduce the dose of ALUNBRIG for patients with severe hepatic impairment.

Renal Impairment: Reduce the dose of ALUNBRIG for patients with severe renal impairment.

Lactation: Advise not to breastfeed.

Please see accompanying full Prescribing Information.

The personal information you provide may be shared with Takeda, its affiliates and companies working with Takeda for the purpose of completing your registration for this program and as required by law. Takeda or companies working with Takeda may also send you information about lung cancer, Takeda products and services, and other health-related topics using the contact information you provide.

Sponsored by Takeda Oncology. Please note that this is not a continuing medical education (CME) program.

All trademarks are the property of their respective owners.
©2020 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
All rights reserved. 08/20 USO-BRG-0062



ONCOLOGY